[Translation] A phase III monotherapy evaluating the efficacy and safety of atezolizumab (an anti-PD-L1 antibody) in patients with stage IV non-squamous or squamous non-small cell lung cancer with high PD-L1 expression and chemotherapy naïve arm multicenter study
本研究将在PD-L1高表达、未接受过化疗、无EGFR敏感突变/ALK融合IV期非鳞状或鳞状非小细胞肺癌(NSCLC)患者中,评估阿替利珠单抗(抗PD-L1抗体)的疗效和安全性。
[Translation] This study will evaluate atezolizumab (anti-PD therapy) in patients with high PD-L1 expression, chemotherapy-naïve, stage IV non-squamous or squamous non-small cell lung cancer (NSCLC) without EGFR-sensitive mutations/ALK fusions. -L1 antibody) efficacy and safety.